EMJ Dermatology 6 [Suppl 3] . 2019

| View in Fullscreen

Journal Info

Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.